Ginkgo Bioworks Inc.
DNA | NYSE
$7.98
+$0.10 (+1.27%)
At close: Sep 21, 2026, 4:00 PM ET
$7.90
-$0.08 (-1.00%)
Pre-market:
Sep 22, 2026, 5:48 AM ET
Company Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Jason Kelly | Co-Founder, Co-COO, CEO & Director |
| Jennifer Wipf | Co-Chief Operating Officer |
| Steven Coen | Chief Financial Officer |
| Austin Che | Co-Founder & Head of Strategy |
| Bartholomew Canton | Co-Founder & CTO |
| Brian O'sullivan | Head of Commercial |
| Daniel Marshall | Senior Manager of Communications & Ownership |
| Karen Tepichin | General Counsel & Secretary |
| Reshma Shetty | Co-Founder, President & Director |
| Thomas Knight Jr. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2026 | 4 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 20, 2026 | 4 | Filing |
| Jun 15, 2026 | 4 | Filing |
Ginkgo Bioworks Inc.
| Country | United States |
| IPO Date | Apr 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 485 |
| CEO | Jason Kelly |
Contact Details
27 Drydock Avenue Boston,
Massachusetts 02210 United States
Stock Details
| Ticker Symbol | DNA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001830214 |
| CUSIP Number | 37611X209 |
| ISIN Number | US37611X2099 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove DNA